SWM
CLVS

Spire Wealth Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Spire Wealth Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,000
Closed -$7K – 2719
2022
Q2 		$7K Hold
4,000
– – ﹤0.01% 2057
2022
Q1 		$8K Hold
4,000
– – ﹤0.01% 2136
2021
Q4 		$11K Hold
4,000
– – ﹤0.01% 2360
2021
Q3 		$18K Hold
4,000
– – ﹤0.01% 1914
2021
Q2 		$23K Hold
4,000
– – ﹤0.01% 1827
2021
Q1 		$28K Buy
+4,000
New +$26.8K ﹤0.01% 2011

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Spire Wealth Management's CLVS Position: Q3 2022 in Review

Spire Wealth Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 4,000 shares — an estimated $7K sold.

Spire Wealth Management first reported a position in CLVS in Q1 2021 and held it in 6 quarters. The position peaked at $28K in Q1 2021. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Spire Wealth Management reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Spire Wealth Management sold 4,000 Clovis Oncology, Inc. shares in Q3 2022, an estimated $7K.
  • Spire Wealth Management first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 6 quarters.
  • Spire Wealth Management's Clovis Oncology, Inc. position peaked at $28K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.